Issat Tadeusz, Nowis Dominika, Legat Magdalena, Makowski Marcin, Klejman Marcin P, Urbanski Jakub, Skierski Janusz, Koronkiewicz Miroslawa, Stoklosa Tomasz, Brzezinska Agnieszka, Bil Jacek, Gietka Jan, Jakóbisiak Marek, Golab Jakub
Department of Immunology, Center of Biostructure, The Medical University of Warsaw, 02-097 Warsaw, Poland.
Int J Oncol. 2007 Jun;30(6):1413-25.
The aim of the present study was to examine the potential antitumor activity of lovastatin and other statins together with pamidronate, a second generation bisphosphonate (BP), against tumor cell lines. Cytostatic/cytotoxic effects were measured using crystal violet assay. Regulation of the cell cycle and induction of apoptosis were evaluated using flow cytometry and Western blotting, migration of tumor cells was measured in a scratch wound assay and their invasiveness was measured with a Matrigel-invasion assay. Antitumor effects of the combination treatment were evaluated in a murine PANC 02 pancreatic adenocarcinoma model. Combination of pamidronate and lovastatin produced potentiated cytostatic/cytotoxic effects against breast and pancreatic cancer cell lines. The combination was also effective in inhibition of tumor cell adhesion to collagen IV and fibronectin and interfered with migration and invasiveness of tumor cells. Neither pamidronate nor lovastatin alone affected tumor growth in mice but the combination treatment resulted in retardation of tumor growth and prolongation of mouse survival. The combination of statins and pamidronate, a second generation bisphosphonate, demonstrates promising antitumor effects at doses readily achievable in patients. This combination holds promise for future clinical studies.
本研究的目的是检测洛伐他汀和其他他汀类药物与第二代双膦酸盐(BP)帕米膦酸联合使用对肿瘤细胞系的潜在抗肿瘤活性。使用结晶紫测定法测量细胞生长抑制/细胞毒性作用。使用流式细胞术和蛋白质免疫印迹法评估细胞周期调控和细胞凋亡诱导情况,通过划痕试验测量肿瘤细胞的迁移能力,并使用基质胶侵袭试验测量其侵袭能力。在小鼠PANC 02胰腺腺癌模型中评估联合治疗的抗肿瘤效果。帕米膦酸和洛伐他汀联合使用对乳腺癌和胰腺癌细胞系产生了增强的细胞生长抑制/细胞毒性作用。该联合用药在抑制肿瘤细胞与IV型胶原和纤连蛋白的黏附方面也有效,并干扰了肿瘤细胞的迁移和侵袭能力。单独使用帕米膦酸或洛伐他汀均未影响小鼠体内肿瘤的生长,但联合治疗导致肿瘤生长迟缓并延长了小鼠存活时间。他汀类药物与第二代双膦酸盐帕米膦酸联合使用,在患者易于达到的剂量下显示出有前景的抗肿瘤效果。这种联合用药有望用于未来的临床研究。